EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2

Naveen Kumar, Adrianna Bilinska, Elena Menéndez, Sarah Stephan, Frank Rösch, Axel Rominger, Eleni Gourni

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08078-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Naveen Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 1-Ring, Drug Design, Radiopharmaceuticals, Polyethylene Glycols. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bern.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study evaluated the imaging performance, tumor retention, and therapeutic potential of two new FAPI homodimers, DOTAGA.Glu 2 .(FAPI) 2 and DOTAGA.PEG 2 .Glu.(FAPI) 2 , specifically designed to improve FAP-targeted tumor retention.

Methods

DOTAGA.Glu 2 .(FAPI) 2 and DOTAGA.PEG 2 .Glu.(FAPI) 2 were radiolabeled with gallium-68 and lutetium-177. In vitro studies included lipophilicity, protein binding, saturation binding, internalization and externalization using FAP + CAFs. In vivo evaluation in PC3-mice comprised biodistribution, metabolic stability, blood and organ clearance, PET/SPECT/CT imaging, and autoradiography. Therapeutic efficacy was assessed using fractionated radioligand therapy with [ 177 Lu]Lu-DOTAGA.Glu 2 .(FAPI) 2 , as monotherapy or combined with everolimus.

Results

All radioligands showed > 99% radiochemical purity, high FAP affinity (K d : 0.9–1.5 nM), hydrophilic profiles (LogD octanol/PBS ≤-3), and low protein binding (< 10%). They exhibited high internalization and low externalization (~ 20% for [ 177 Lu]Lu-DOTAGA.Glu 2 .(FAPI) 2 and ~ 35% for [ 177 Lu]Lu-DOTAGA.PEG 2 .Glu.(FAPI) 2 ). The 68 Ga-labeled radiotracers displayed sustained tumor uptake up to 3 h p.i. (> 14%I.A./g) with increasing tumor-to-organ ratios. For the 177 Lu-labeled analogues the initial uptake was comparable (~ 15%I.A./g at 4 h p.i.), with [ 177 Lu]Lu-DOTAGA.Glu 2 .(FAPI) 2 , showing even improved retention compared to [ 177 Lu]Lu-DOTAGA.PEG 2 .Glu.(FAPI) 2 (4.2 ± 0.5 vs. 1.2 ± 0.02%I.A./g at 96 h). Blood clearance was rapid and biphasic, with faster kinetics for DOTAGA.Glu 2 .(FAPI) 2 . For the same compound, tumor half-life was significantly prolonged (44.5 vs. 19 h), resulting in 2-fold higher tumor exposure (AUC: 971 ± 74 vs. 542 ± 28%I.A.×h/g). Imaging confirmed high tumor-to-background ratios, while autoradiography revealed heterogeneous intratumoral FAP distribution. Fractionated therapy significantly inhibited tumor growth and improved survival, further enhanced by everolimus.

Conclusion

DOTAGA.Glu 2 .(FAPI) 2 demonstrates superior tumor retention, favorable pharmacokinetics, and enhanced therapeutic efficacy, supporting its potential for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 1-RingDrug DesignRadiopharmaceuticalsPolyethylene GlycolsAnimalsMiceHumansTissue DistributionLutetiumCell Line, TumorFibroblast Activation Protein AlphaGallium RadioisotopesRadioisotopesPositron Emission Tomography Computed TomographySingle Photon Emission Computed Tomography Computed Tomography

Stichwörter der Autor:innen

Combination therapyEverolimusFAP inhibitorFractionated monotherapyHomodimeric FAPIgallium-68lutetium-177

Substanzen

LutetiumGallium-68Fibroblast Activation Protein AlphaLutetium-177Gallium RadioisotopesRadioisotopesHeterocyclic Compounds, 1-RingRadiopharmaceuticalsPolyethylene Glycols

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
  • Department of Biomedical Research, University of Bern, Bern, Switzerland.
  • Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Department of Chemistry-TRIGA site, Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland. eleni.gourni@insel.ch.
  • Department of Biomedical Research, University of Bern, Bern, Switzerland. eleni.gourni@insel.ch.

Förderung

  • University of Bern

Zitieren

APA

Kumar, N., Bilinska, A., Menéndez, E., Stephan, S., Rösch, F., Rominger, A., & Gourni, E. (2026). Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08078-9

Vancouver

Kumar N, Bilinska A, Menéndez E, Stephan S, Rösch F, Rominger A, et al. Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08078-9

BibTeX
@article{Kumar2026,
  author = {Kumar, Naveen and Bilinska, Adrianna and Menéndez, Elena and Stephan, Sarah and Rösch, Frank and Rominger, Axel and Gourni, Eleni},
  title = {Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08078-9}
}
Kostenlos starten →